EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Single-session radiosurgery for Cushing disease after failed resection: a retrospective single-center cohort study

Bardia Hajikarimloo, Salem M Tos, Yuki Shinya, Onam Verma, Evan Mancini, Sean Morgan, Zhenye Li, Georgios Mantziaris, Gregory K Hong, Jason P Sheehan

The Journal of Clinical Endocrinology & Metabolism · 2026-11-10

DOI: 10.1210/clinem/dgag369 ↗
AbstractBibliografische Angaben

Abstract

Abstract Context Cushing disease (CD) from an adrenocorticotropic hormone-secreting pituitary adenoma causes substantial morbidity when hypercortisolism persists or recurs after transsphenoidal surgery (TSS). Objective To define endocrine control, radiographic response, toxicity, and predictors after single-session Gamma Knife radiosurgery for residual or recurrent CD. Design Retrospective single-center cohort study, 1990-2026; median endocrine follow-up 54 months. Setting Single academic tertiary referral center. Patients 186 adults with residual or recurrent CD after ≥1 TSS and ≥12 months of follow-up. Median age 40.8 years; 78.0% female. Intervention Single-session frame-based SRS (median prescription dose 23.0 Gy; maximum dose 48.0 Gy). Main Outcome Measures Prespecified primary outcome was durable biochemical control off medications (sustained 24-hour urinary free cortisol [UFC] normalization without cortisol-lowering therapy), modeled with competing-risks methodology. Results UFC normalized in 152 patients (81.7%), including 134 (72.0%) off all medications. Cumulative incidence of durable off-medication control was 51% (95% CI: 44-58%) at 12 months and 64% (95% CI: 56-71%) at 120 months. New endocrinopathy reached 42% (95% CI: 32-52%) at 120 months; new visual deficit occurred in 3.2%. A TSS-to-SRS interval <6 months independently predicted higher durable control (P < .001), while higher baseline AM cortisol (P < .001), whole-sella treatment (P = .013), and female gender (P = .027) predicted lower durable control. Higher maximum dose was the sole independent predictor of new endocrinopathy (P = .009). Conclusion Single-session SRS achieves durable medication-free control in approximately two-thirds of patients with residual or recurrent CD, with excellent tumor control and meaningful delayed endocrine toxicity warranting long-term surveillance.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →